Human Papillomavirus (HPV) Vaccination

Context

The Government of India announced the formal rollout of a nationwide Human Papillomavirus (HPV) vaccination programme. Aimed at eliminating cervical cancer, the initiative focuses on adolescent girls as a primary preventive measure, marking one of India's most significant public health pushes for women's wellness.

About the News

The Vaccine: A recombinant vaccine that triggers an immune response using virus-like genetic material (no live virus).
The Goal: To protect against high-risk HPV variants that cause nearly 85% of all cervical cancers in India.
National Statistics (2026):
- Annual Burden: India reports approximately 1.27 lakh new cases and nearly 80,000 deaths annually.
- Mortality Rate: Roughly one woman dies every eight minutes from this preventable disease.
- Global Share: India accounts for nearly one-fifth of the global cervical cancer burden.

Vector for HPV

Primary Cause: Persistent infection with high-risk Human Papillomavirus (HPV) types, particularly 16 and 18, which are oncogenic.
Transmission: A common sexually transmitted infection (STI) spread through skin-to-skin contact.
Progression: It typically takes 10 to 20 years for a persistent HPV infection to develop into invasive cervical cancer, providing a wide window for early prevention via vaccination and screening.

Key Features of the Initiative

Target Group: Girls who turn 14 years old each year (an annual cohort of ~1.15 crore girls). Vaccination at this age provides the strongest immune response and occurs before potential exposure.
Vaccine Used: The government is utilizing Gardasil-4 (quadrivalent), which protects against four HPV types: 16 & 18 (cancer-causing) and 6 & 11 (causing genital warts).
- Note: While the indigenous Cervavac (Serum Institute of India) is available in the private market, the government currently uses Gardasil for the national drive through its partnership with Gavi, the Vaccine Alliance.
Dosage: A single-dose schedule has been adopted based on 2022 WHO recommendations and ICMR guidance, proving as effective as multi-dose regimens for this age group.
Implementation: Voluntary and free of cost at government facilities (Ayushman Arogya Mandirs, district hospitals).
Tracking: Managed through the U-WIN digital platform for seamless registration and appointment booking.

Significance

High Efficacy: Vaccination can reduce the risk of cervical cancer by 90% to 95% when administered during the early teens.
Equity: Removing the "price barrier" (private vaccines cost ₹3,000–₹4,000 per dose) ensures that girls from all socio-economic backgrounds are protected.
Economic Impact: Reducing the cancer burden directly improves long-term economic productivity and reduces the public healthcare expenditure on advanced cancer treatments.

Way Forward

Universal Immunization: While currently a special campaign, the aim is to eventually integrate HPV shots into the Universal Immunisation Programme (UIP).
Screening Integration: Combining vaccination for the young with regular screening (VIA/HPV DNA tests) for women aged 30–65.
Awareness: Overcoming vaccine hesitancy through community-level sensitisation by ASHA workers and school-based outreach.

Conclusion

The 2026 HPV vaccination drive is a historic step toward achieving the WHO's global target of eliminating cervical cancer by 2030. By prioritizing 14-year-old girls, India is investing in a future where "Swastha Nari" (Healthy Woman) forms the foundation of a resilient nation.

Human Papillomavirus (HPV) Vaccination